Evidence map›Paper›PMID 37345396›Full record

ArticleTuberkuloz ve toraks2023

[Prognosis of lung cancer patients followed in the intensive care unit: A cross-sectional study].

Şeyda Nur Özpınar, Aslıhan Gürün Kaya, Miraç Öz, Serhat Erol, Fatma Arslan, Aydın Çiledağ, Akın Kaya

Abstract readEnglish Abstract
In one paragraph

Article in Tuberkuloz ve toraks, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Şeyda Nur ÖzpınarDepartment of Chest Diseases, Ankara University Faculty of Medicine, Ankara, Türkiye.
Aslıhan Gürün KayaDepartment of Chest Diseases, Ankara University Faculty of Medicine, Ankara, Türkiye.
Miraç ÖzDepartment of Chest Diseases, Ankara University Faculty of Medicine, Ankara, Türkiye.
Serhat ErolDepartment of Chest Diseases, Ankara University Faculty of Medicine, Ankara, Türkiye.
Fatma ArslanDepartment of Chest Diseases, Ankara University Faculty of Medicine, Ankara, Türkiye.
Aydın ÇiledağDepartment of Chest Diseases, Ankara University Faculty of Medicine, Ankara, Türkiye.
Akın KayaDepartment of Chest Diseases, Ankara University Faculty of Medicine, Ankara, Türkiye.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Lung cancer is the most common solid organ malignancy requiring intensive care unit (ICU) admission. For many years, lung cancer patients were not considered in the priority patient category for admission to ICU because of their high mortality rate and poor response to therapy. Considering the developments in treatment modalities, we aimed to reevaluate the prognosis of patients with lung cancer in the ICU. Materials and Methods: Patients characteristics, date of diagnosis, the reason for ICU admission, the stage of cancer, histopathological type, history of chemotherapy, radiotherapy, or surgery for cancer, and APACHE-II and Charlson comorbidity index (CCI) were recorded retrospectively. Result: A total of 100 patients had a mean age of 69.7 ± 9.0 years. Among these patients, 18% had small cell lung cancer, while 82% had non-small cell lung cancer. The in-hospital mortality rate was 69% for all patients, while among those discharged from the ICU, the first 6-month mortality rate was 58.1%. The median survival time was 8.2 months. Advanced age, the need for mechanical ventilation, the need for vasopressors, a high APACHE -II, and the CCI all reduced survival in multivariate analysis, whereas chemotherapy and surgical history improved survival. Conclusions: Patients admitted to the ICU with lung cancer continue to experience a high mortality rate. However, identifying the factors that are associated with survival can be crucial in establishing care plans and prioritizing ICU admission for further therapy.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsAgedCross-Sectional StudiesHospital MortalityHumansIntensive Care UnitsMiddle AgedPrognosisRetrospective Studies

Identifiers

PMID37345396
PMCPMC10795251

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.